CT引导下经皮微波消融治疗原发性肝细胞癌的疗效
研究纳入220例原发性肝细胞癌患者,接受CT引导下经皮微波消融并随访2年,1年和2年累积总生存率分别为95.45%和89.09%,1年和2年无进展生存率分别为80.90%和62.73%。Child-Pugh评分(p=0.030)和BCLC分级(p=0.012)是总生存的独立危险因素,肿瘤结节数目是复发的独立危险因素,未观察到致命性并发症。
要点
- BCLC C级患者1年和2年累积总生存率分别为89.09%和74.54%。
- BCLC C级中伴血管侵犯或肿瘤相关症状者总生存较差(p=0.011)。
- Child-Pugh评分(p=0.030)和BCLC分级(p=0.012)为总生存独立危险因素。
核心结论
- CT引导下经皮微波消融可能是肝细胞癌患者有效且安全的治疗选择。
研究设计与样本
- 研究收集并分析220例接受CT引导下微波消融的原发性肝细胞癌患者数据,随访2年,分析总生存和无进展生存的独立危险因素。
诊断标准与关键数值
- 全部随访病例1年和2年累积总生存率分别为95.45%和89.09%。
- 全部随访病例1年和2年累积无进展生存率分别为80.90%和62.73%。
- BCLC C级患者(n=60)1年和2年累积总生存率分别为89.09%和74.54%。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
AIM: To evaluate the treatment efficacy and potential complications of computed tomography (CT)-guided microwave ablation for primary hepatocellular carcinoma (HCC).
MATERIALS AND METHODS: Data were collected and analysed from 220 HCC patients treated with CT-guided microwave ablation and followed up for 2 years. Independent risk factors for overall survival and progression-free survival (PFS) were analysed.
RESULTS: Among all cases followed, the cumulative overall survival rates at 1 and 2 years were 95.45% and 89.09%. The cumulative 1- and 2-year PFS rates were 80.90% and 62.73%. For patients with Barcelona Clinic Liver Cancer (BCLC) class C (n=60), the cumulative 1- and 2-year overall survival rates were 89.09% and 74.54%. In this group, patients with tumour invasion of blood vessels or tumour-related symptoms suffered a worse overall survival compared to those without (p=0.011). No fatal complications were observed. Child-Pugh score (p=0.030) and BCLC class (p=0.012) were independent risk factors for overall survival. The number of tumour nodules was an independent risk factor for reoccurrence.
CONCLUSION: CT-guided percutaneous microwave ablation could be an effective and safe treatment option for HCC patients.
引用
- Yin T, Li W, Zhao P, et al. Treatment efficacy of CT-guided percutaneous microwave ablation for primary hepatocellular carcinoma. Clin Radiol. 2016. PMID: 27890422. doi:10.1016/j.crad.2016.10.022
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。